Research to find new antibiotics is crucial to keep the mortality rate for infectious diseases in the world.
Meanwhile, the presence of bacteria that is resistant to almost all antibiotics low in Sweden compared with other European countries. Resistant Staphylococcus aureus, MRSA is the most common type, but there are several other tribes.
Previously distributed multi-resistant bacteria often in health care, but today many are infected while traveling in other countries. Globalization has this back. Three of the ten leading causes of death in the world are infections and account for 16 percent of deaths. Did not penicillin and vaccines have been many more would have suffered and died. Especially children are vulnerable to infections and in low-income countries still die many of diarrhea and malaria.
In our part of the world die most of cardiovascular diseases and ailments of the respiratory system. But multi-resistant bacteria are taking more and more lives in Europe and recalls how dangerous infections may be for humans. To effectively treat infections are also of paramount importance for patients to survive chemotherapy and surgery.
In order to cope with future challenges from microbes, which are amazing survivors, are also needed new drugs. Enough bacteria have already cracked the code for the preparations that exist today.
However, it will not be long before new drugs that attacks multiresistant bacteria come on the market. To develop new antibiotics has long given lower priority by the pharmaceutical industry because it is very costly to develop, test, obtain permits and to launch a new medicine. Future revenues are relatively small compared to developing drugs against common diseases in the developed world. Not to bacteria to adapt to new drugs must be used sparingly. It will not permit a single antibiotic to clear all bacterial infections.
But it’s a rush. This spring was found the first case of a feared super-bacteria which are resistant to all antibiotics, in a patient in the United States. “Post-antibiotic era is dangerously close,” says Otto Cars, professor of infectious diseases and founder of the international network ReAct against antibiotic resistance.
More than those treated with antibiotics affected by the use. This applies to both animals and people. The pharmaceutical industry also appears on a through politicized market. Public players approves drugs regulate how information about them may be presented, how the pricing looks and finances a substantial share of consumption. World countries have an important role to co-finance new antibiotics.
In September, the UN General Assembly to address the threat posed by multidrug-resistant bacteria. WHO calls its members to develop their own action plans by 2017.
Plenty so. We need broad agreements for distribution, sales and financing of antibiotics. The microscopic infectious agents is a global problem in the same way as climate change.
No comments:
Post a Comment